June 28, 2024
Pressure Points: Understanding Their Role in Self-Defense and Health
Pressure Points, Self-Defense, Knockout Techniques, Acupressure, Health Benefits, Pain Relief
Rovi Receives Acquisition Offers for CDMO Unit Worth €2B to €3B
Rovi, CDMO, Acquisition Offers, Private Equity, Biogen, Deal Making
Fresenius Medical Care Achieves 25x Faster Kidney Disease Insights with Privacy Analytics
Fresenius Medical Care, kidney disease, data analytics, patient privacy, global database, healthcare insights
AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio
AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech
Daiichi Sankyo Secures $47 Million Victory in ADC Patent Arbitration Against AstraZeneca
Daiichi Sankyo, AstraZeneca, ADC Patent Arbitration, $47 Million Settlement
Ginkgo Bioworks to Lay Off Up to 400 Employees Amid Cost-Cutting Measures
Ginkgo Bioworks, layoffs, cost-cutting, biosecurity, cell programming, workforce reduction
Alumis Secures $250 Million in Downsized Initial Public Offering
Alumis, Immunology Biotech, IPO, Initial Public Offering, Funding, Biotechnology
Lykos Faces Setback as ICER Concludes Insufficient Evidence for MDMA-Based PTSD Treatment
Lykos Therapeutics, MDMA, PTSD, ICER, Insufficient Evidence, Clinical Trials, FDA Approval
FDA Rejects Merck-Daiichi Sankyo’s Lung Cancer Drug, Approves New Treatments for COPD and Lymphoma
FDA, Merck, Daiichi Sankyo, NSCLC, COPD, Lymphoma, Patritumab Deruxtecan, Ensifentrine, Epkinly
FDA Approves EPKINLY (Epcoritamab-Bysp) for Relapsed or Refractory Follicular Lymphoma
EPKINLY, epcoritamab-bysp, follicular lymphoma, FDA approval, relapsed or refractory, bispecific antibody, T-cell engaging, subcutaneous treatment